Bristol-Myers Squibb Company (BMY) Board Elects Charles Bancroft Chief Financial Officer

Bristol-Myers Squibb Company (BMY) Board Elects Charles Bancroft Chief Financial Officer


NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY - News) today announced that the company's Board of Directors has elected Charles Bancroft chief financial officer effective April 8, 2010. In this role, Mr. Bancroft will be responsible for directing and managing the company's fiscal operations and the global finance organization. Mr. Bancroft has been serving as the company's acting CFO since January 1, 2010. He will report to Lamberto Andreotti, president and chief operating officer, and chief executive officer designate.

"The Board of Directors, Jim Cornelius and I have great confidence in Charlie's ability to provide the financial stewardship needed to help drive shareholder value," said Mr. Andreotti. "His tenure with Bristol-Myers Squibb has been marked by strong leadership and depth of experience in finance, earning him trust and respect from his peers across all functions and within the entire finance organization."

Mr. Bancroft joined Bristol-Myers Squibb in 1984 and has since held positions of increasing responsibility within the finance organization, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec. He received a B.S. in Accounting from Drexel University, his M.B.A. in Finance from Temple University and is a certified public accountant.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.

Contact:

Bristol-Myers Squibb Company Media: Tracy Furey, 609-252-3208 [email protected] or Investors: John Elicker, 609-252-4611 [email protected]
 
 
 

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.